

Sean E O'brien

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10940789/publications.pdf>

Version: 2024-02-01

15
papers

1,965
citations

623734

14
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

2823
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Targeting the nucleolus for cancer-specific activation of p53. <i>Drug Discovery Today</i> , 2014, 19, 259-265. | 6.4 | 40 |
| 2 | Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. <i>Cancer Letters</i> , 2012, 322, 113-118. | 7.2 | 67 |
| 3 | Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells. <i>PLoS ONE</i> , 2012, 7, e49193. | 2.5 | 51 |
| 4 | Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 602-606. | 2.8 | 111 |
| 5 | CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 994-1005. | 4.1 | 96 |
| 6 | Synthesis and SAR of inhibitors of protein kinase CK2: Novel tricyclic quinoline analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 45-48. | 2.2 | 16 |
| 7 | Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3327-3331. | 2.2 | 31 |
| 8 | Unprecedented Selectivity and Structural Determinants of a New Class of Protein Kinase CK2 Inhibitors in Clinical Trials for the Treatment of Cancer. <i>Biochemistry</i> , 2011, 50, 8478-8488. | 2.5 | 154 |
| 9 | 7-(4H-1,2,4-Triazol-3-yl)benzo[<i>c</i>][2,6]naphthyridines: A novel class of Pim kinase inhibitors with potent cell antiproliferative activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 6687-6692. | 2.2 | 50 |
| 10 | Discovery and SAR of 5-(3-Chlorophenylamino)benzo[<i>c</i>][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for the Treatment of Cancer. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 635-654. | 6.4 | 259 |
| 11 | Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. <i>Molecular and Cellular Biochemistry</i> , 2011, 356, 37-43. | 3.1 | 130 |
| 12 | Novel potent pyrimido[4,5- <i>c</i>]quinoline inhibitors of protein kinase CK2: SAR and preliminary assessment of their analgesic and anti-viral properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1687-1691. | 2.2 | 28 |
| 13 | Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth. <i>Cancer Research</i> , 2011, 71, 1418-1430. | 0.9 | 482 |
| 14 | CX-4945, an Orally Bioavailable Selective Inhibitor of Protein Kinase CK2, Inhibits Prosurvival and Angiogenic Signaling and Exhibits Antitumor Efficacy. <i>Cancer Research</i> , 2010, 70, 10288-10298. | 0.9 | 449 |
| 15 | Abstract 2763: Utility of clinical biomarkers for detecting protein kinase CK2 inhibition: A report from the phase I trial of CX-4945. <i>Cancer Research</i> , 2010, 70, 2763-2763. | 0.9 | 1 |